Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 8:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 131 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Osteoporosis, Post-menopausal Clear all
Completed Phase 3 Interventional Results available

3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs

NCT00718861
View directory record Official record
Conditions
Post-menopausal Osteoporosis
Interventions
Placebo, Zoledronic acid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
65 Years and older · Female only
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
10
States / cities
San Diego, California • Lakewood, Colorado • Gainesville, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2014 · Synced Jun 10, 2026, 8:09 PM EDT
Completed Phase 4 Interventional

Risedronate in the Prevention of Osteoporosis in Postmenopausal Women

NCT00402441
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Risedronate (HMR4003)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
45 Years and older · Female only
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 28, 2009 · Synced Jun 10, 2026, 8:09 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Combination Osteogenic Therapy in Established Osteoporosis

NCT00018447
View directory record Official record
Conditions
Osteoporosis, Post-Menopausal
Interventions
PTH 1-34, MFPSR-fluoride
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
60 Years to 80 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2003
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2009 · Synced Jun 10, 2026, 8:09 PM EDT
Completed Not applicable Interventional Results available

Texture Analysis for Postmenopausal Osteoporosis

NCT00145977
View directory record Official record
Conditions
Osteoporosis, Osteopenia
Interventions
Alendronate, Calcium Citrate, Vitamin D
Drug · Dietary Supplement
Lead sponsor
University of Chicago
Other
Eligibility
59 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Jun 10, 2026, 8:09 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption

NCT01750086
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Teriparatide 40-mcg subcutaneous injection, Denosumab Injection, Alendronate Oral Tablet
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 26, 2017 · Synced Jun 10, 2026, 8:09 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Anabolic Therapy in Postmenopausal Osteoporosis

NCT05010590
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Romosozumab, Denosumab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jun 10, 2026, 8:09 PM EDT
Completed Phase 3 Interventional Results available

DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis

NCT00048074
View directory record Official record
Conditions
Post Menopausal Osteoporosis
Interventions
ibandronate [Bonviva/Boniva]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
55 Years to 80 Years · Female only
Enrollment
1,395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
19
States / cities
Little Rock, Arkansas • Irvine, California • Rancho Mirage, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Jun 10, 2026, 8:09 PM EDT
Completed Phase 1 Interventional

A Study to Determine the Patient Preference Between Zosano Pharma Parathyroid Hormone (ZP-PTH) Patch and Forteo Pen

NCT02478879
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
ZP-PTH, FORTEO
Drug
Lead sponsor
Zosano Pharma Corporation
Industry
Eligibility
55 Years to 85 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Aug 22, 2016 · Synced Jun 10, 2026, 8:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Soy Isoflavones on Bone Mineral Density and Physical Performance Indices

NCT00661856
View directory record Official record
Conditions
Osteoporosis
Interventions
Soy protein
Dietary Supplement
Lead sponsor
Creighton University
Other
Eligibility
55 Years to 72 Years · Female only
Enrollment
203 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2004
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 20, 2008 · Synced Jun 10, 2026, 8:09 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Blackcurrants Modify Gut Microbiota and Reduce Osteoporosis Risk in Postmenopausal Females

NCT07365514
View directory record Official record
Conditions
Postmenopausal Osteoporosis, Gut Microbiome, Menopause
Interventions
Blackcurrant (BC) extract, Placebo
Drug
Lead sponsor
University of Connecticut
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
159 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Jun 10, 2026, 8:09 PM EDT
Completed Phase 3 Interventional Results available

Comparative Efficacy and Safety Study of RGB-14-P and Prolia® in Women With Postmenopausal Osteoporosis

NCT05087030
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
RGB-14-P, Prolia®
Drug
Lead sponsor
Gedeon Richter Plc.
Industry
Eligibility
60 Years to 90 Years · Female only
Enrollment
473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Miami, Florida • Miami Lakes, Florida • Decatur, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Jun 10, 2026, 8:09 PM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Effect of Blueberries on Bone Turnover

NCT02630797
View directory record Official record
Conditions
Osteoporosis, Postmenopausal, Bone Loss, Age-related
Interventions
Blueberry Baseline, Blueberry Low, Blueberry Medium, Blueberry High
Dietary Supplement
Lead sponsor
Purdue University
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated May 6, 2018 · Synced Jun 10, 2026, 8:09 PM EDT
Completed Phase 4 Interventional

OPTAMISE: Clinical Effectiveness of Teriparatide After Alendronate or Risedronate Therapy in Osteoporotic Postmenopausal Women

NCT00130403
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
risedronate sodium
Drug
Lead sponsor
Sanofi
Industry
Eligibility
55 Years to 85 Years · Female only
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 10, 2011 · Synced Jun 10, 2026, 8:09 PM EDT
Completed Phase 4 Interventional

A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia

NCT02604836
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Ibandronate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Female only
Enrollment
1,711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
142
States / cities
Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 128 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jun 10, 2026, 8:09 PM EDT
Completed No phase listed Observational

A Pilot Study of Bone Mineral Density in Postmenopausal Women After Treatment for Breast Cancer

NCT00399321
View directory record Official record
Conditions
Postmenopausal Bone Loss, Breast Cancer
Interventions
Not listed
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 4, 2017 · Synced Jun 10, 2026, 8:09 PM EDT
Completed Phase 3 Interventional Results available

Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis

NCT01657162
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Alendronate
Drug
Lead sponsor
Radius Health, Inc.
Industry
Eligibility
50 Years to 85 Years · Female only
Enrollment
1,139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Lakewood, Colorado • Hialeah, Florida • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Jun 10, 2026, 8:09 PM EDT
Completed No phase listed Observational

Study of Bone Histomorphometry, Microarchitecture, and Matrix Structure in Patients Receiving Alendronate or Risedronate

NCT00778154
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Not listed
Lead sponsor
Warner Chilcott
Industry
Eligibility
Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
7
States / cities
Palm Desert, California • Lakewood, Colorado • Decatur, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Jun 10, 2026, 8:09 PM EDT
Completed Phase 3 Interventional Results available

Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis

NCT01631214
View directory record Official record
Conditions
Postmenopausal Women With Osteoporosis
Interventions
Romosozumab, Alendronate, Placebo to Romosozumab, Placebo to Alendronate
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
55 Years to 90 Years · Female only
Enrollment
4,093 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
32
States / cities
Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Jun 10, 2026, 8:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Radius Loading in Primary Hyperparathyroidism

NCT01571843
View directory record Official record
Conditions
Primary Hyperparathyroidism, Bone Diseases, Metabolic, Osteoporosis, Postmenopausal, Bone Loss, Postmenopausal
Interventions
Forearm exercise program, Walking program
Other
Lead sponsor
Columbia University
Other
Eligibility
45 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2015 · Synced Jun 10, 2026, 8:09 PM EDT
Completed Phase 3 Interventional Results available

A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis

NCT02157948
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Denosumab (CP2), Denosumab (CP4)
Drug
Lead sponsor
Amgen
Industry
Eligibility
55 Years to 100 Years · Female only
Enrollment
394 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
10
States / cities
Santa Maria, California • South Lake Tahoe, California • Lakewood, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2017 · Synced Jun 10, 2026, 8:09 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women

NCT00918749
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
150 mg, 75 mg, 100 mg
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
45 Years to 80 Years · Female only
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
6
States / cities
Daytona Beach, Florida • Fort Myers, Florida • Honolulu, Hawaii + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2015 · Synced Jun 10, 2026, 8:09 PM EDT
Completed Phase 4 Interventional Results available

Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic Women

NCT00927186
View directory record Official record
Conditions
Osteoporosis, Post-menopausal
Interventions
Teriparatide, Zoledronic Acid
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 89 Years · Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
9
States / cities
Lakewood, Colorado • Atlanta, Georgia • Gainesville, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2013 · Synced Jun 10, 2026, 8:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Patient- and Physician-Based Osteoporosis Education

NCT00073190
View directory record Official record
Conditions
Osteoporosis, Osteoporosis, Postmenopausal
Interventions
Osteoporosis Education
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
65 Years and older
Enrollment
30,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 15, 2013 · Synced Jun 10, 2026, 8:09 PM EDT
Completed Phase 4 Interventional Results available

A Study Comparing Monthly Boniva (Ibandronate) and Weekly Risedronate in Women With Post-Menopausal Osteoporosis.

NCT00377234
View directory record Official record
Conditions
Post Menopausal Osteoporosis
Interventions
Risedronate, ibandronate [Bonviva/Boniva]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
55 Years to 80 Years · Female only
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
48
States / cities
Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2016 · Synced Jun 10, 2026, 8:09 PM EDT